Who is sponsoring NCT02873546?

NCT02873546 is sponsored by Centre Hospitalier Universitaire de Besancon.

What drugs are being tested in NCT02873546?

Interventions in NCT02873546: transcranial Direct Current Stimulation (tDCS).

What condition does NCT02873546 study?

NCT02873546 studies Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State.

Is NCT02873546 still recruiting?

NCT02873546 is currently status unknown. Last updated 13 October 2017.

Last reviewed 2017-10-13 · How we verify

NCT02873546: ALSTICO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia

Status unknown NA Last updated 13 October 2017

What this trial tests

NA trial testing transcranial Direct Current Stimulation (tDCS) in Alzheimer's Disease in 52 participants. Status unknown.

Timeline

19 July 2013

Primary endpoint
31 January 2018

31 July 2018

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Besancon
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	52
Start date	19 July 2013
Primary completion	31 January 2018
Estimated completion	31 July 2018
Sites	3 locations across France

Drugs / interventions tested

transcranial Direct Current Stimulation (tDCS)

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →
Progressive Primary Aphasia — all drugs for Progressive Primary Aphasia →
Early or Mild State — all drugs for Early or Mild State →

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

60 and older, any sex, with Alzheimer's Disease or Progressive Primary Aphasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left Cortex DorsoLateral PreFrontal (CDLPF) of Alzheimer's or Primary Progressive Aphasia (PPA) patients compared to the application of a placebo tDCS (sham procedure) on cognitive functions, which are evaluated at short term (1 week post-treatment) and mild term (3 weeks post-treatment). After unblinding, patients who received placebo treatment could be received active tDCS.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.
Nystuen KL, McNamee SM, Akula M, Holton KM, et al · · 2024 · cited 18× · PMID 38247923 · DOI 10.3390/bioengineering11010045
Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia.
Roheger M, Riemann S, Brauer A, McGowan E, et al · · 2024 · cited 13× · PMID 38808659 · DOI 10.1002/14651858.cd015067.pub2

Verify or expand the search:

Other trials of transcranial Direct Current Stimulation (tDCS)

Trials testing the same drug.

NCT04206215 — Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome · NA · recruiting
NCT04777149 — Random Noise Stimulation to Enhance Cortical Drive & Improve Hand Function · NA · completed
NCT04978142 — MaST: MEG and Brain Stimulation in Tinnitus · NA · completed
NCT04504422 — tDCS for Dual-task Performance in Patients With PD · NA · completed
NCT03813355 — Evaluation of tDCS Efficacy in Enduring Anorexia Nervosa · NA · terminated

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02873546 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
Last refreshed: 13 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02873546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing